Simply put, we live and breathe healthcare. Being 100% specialised in the Pharmaceutical, Medical Device, MedTech and IVD spaces since 2014, this sole industry focus has seen us grow to become the #1 Healthcare recruiting firm in Japan.
Our Hiring Solutions
Having a deep understanding of our clients and maintaining a superior level of service is our number one priority. We don’t just look for any candidate to introduce, we seek out the candidate to introduce.
Our specialists have combined 100 years of experience in the Japan recruitment market. We understand changing careers is a big decision, and we work with our candidates to ensure a smooth transition.
As one of Titan’s core businesses, the Medical Device & Diagnostics team operates a deep network of clients and candidates covering major global and domestic medical device companies as well as market entry, start up and MedTech & Digital Health related firms.
Pharmaceutical recruiting comprises the largest team at Titan, and its large size allows it to work widely within the Japan market. While it caters primarily to foreign pharma of all sizes, candidates are employed at domestic and global pharma and CRO.
Our people are industry leaders and our network spans deep into various markets that make a difference to the world we live in. While the biotech and medtech world is a key focus, this also includes but is not limited to healthcare services, consulting, and the vast expanses of tech.
INSIGHTFUL SOLUTIONS FOR QUALITY OUTCOMES
Our team is here to help
US Biotech Enters Japan
Our client (US biotech / rare disease) approached Titan Consulting Pharmaceutical team in mid 2019 and shared their Japanese market entry plan and the need to scale quickly.
The Urgent Hire
The Japan Representative Director of a mid-sized US biotech reached out to the Titan Consulting Pharmaceutical team for urgent assistance in sourcing a suitably high caliber professional.
Heathcare & Life Science
This report aim is to provide insight into the recruitment market situation during the Covid-19 pandemic and document any changes and challenges companies have faced.